Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1148 participants.

Also called NCT07536802

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,148 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07536802
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07536802. Randomized; no masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2026-05-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Acronym
AMPACT
Condition
ST-Segment Elevation Myocardial Infarction (STEMI)
Condition
No-Reflow Phenomenon
Condition
Coronary Slow Flow
Condition
Acute Myocardial Infarction
Intervention (Drug)
Adenosine pre-medication
Intervention (Other)
Standard care
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)

Record details

Record id
cardio:ct-nct07536802
Content hash
c169d7a2e5502beffaab6bc9411f48dfc66f6d525b09b8574202aa3176ac8ab3